1
|
Léger M, Auchabie J, Ferrandière M, Parot-Schinkel E, Campfort M, Rineau E, Lasocki S. Erythropoietin to treat anaemia in critical care patients: a multicentre feasibility study. Anaesthesia 2023; 78:979-987. [PMID: 37184109 DOI: 10.1111/anae.16038] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2023] [Indexed: 05/16/2023]
Abstract
Anaemia is common and associated with poor outcomes during and after critical illness. The use of erythropoietin to treat such anaemia is controversial with older studies showing mixed results. In this study, we aimed to evaluate the feasibility of performing a large multicentre randomised controlled trial of erythropoietin in this setting. We randomly allocated patients staying in the ICU for ≥ 72 h with haemoglobin ≤ 120 g.l-1 to either a weekly injection of erythropoietin (40,000 iu, maximum of five injections) or placebo (saline). The primary endpoint was feasibility (as measured by recruitment, randomisation and follow-up rates, and protocol compliance). Secondary endpoints included biological efficacy and clinical outcomes. Forty-two participants were recruited and randomly allocated, all participants received the allocated intervention, but one withdrew their consent and refused the use of their data, leaving 20 in the erythropoietin group and 21 in placebo group. Follow-up was completed for all patients who survived. The overall recruitment rate was 73.7% with 8.4 participants recruited on average per month. The last haemoglobin measured before hospital discharge (or death) was similar between the groups with a mean (SD) haemoglobin of 107 (21) vs. 95 (25) g.l-1 , mean difference (95%CI) 11 (-4-26), g.l-1 , p = 0.154. A large, multicentre randomised controlled trial of erythropoietin to treat anaemia in ICU patients is feasible and necessary to determine effects of erythropoietin on mortality in ICU anaemic patients.
Collapse
Affiliation(s)
- M Léger
- Department of Anaesthesiology and Critical Care, Angers University, CHU Angers, Angers, France
| | - J Auchabie
- Réanimation polyvalente, CH de Cholet, Cholet, France
| | - M Ferrandière
- Department of Anaesthesiology and Critical Care, CHRU Tours, Tours, France
| | - E Parot-Schinkel
- Department of Biostatistics and Methodology, CHU Angers, Angers, France
| | - M Campfort
- Department of Anaesthesiology and Critical Care, Angers University, CHU Angers, Angers, France
| | - E Rineau
- Department of Anaesthesiology and Critical Care, Angers University, CHU Angers, Angers, France
| | - S Lasocki
- Department of Anaesthesiology and Critical Care, Angers University, CHU Angers, Angers, France
| |
Collapse
|
2
|
Lasocki S, Asfar P, Jaber S, Ferrandiere M, Kerforne T, Asehnoune K, Montravers P, Seguin P, Peoc'h K, Gergaud S, Nagot N, Lefebvre T, Lehmann S. Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2021; 25:62. [PMID: 33588893 PMCID: PMC7885380 DOI: 10.1186/s13054-020-03430-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Accepted: 12/07/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes. METHODS In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoietin for 20 ≤ hepcidin < 41 μg/l. Control patients were treated according to standard care (hepcidin quantification remained blinded). Primary endpoint was the number of days spent in hospital 90 days after ICU discharge (post-ICU LOS). Secondary endpoints were day 15 anemia, day 30 fatigue, day 90 mortality and 1-year survival. RESULTS Of 405 randomized patients, 399 were analyzed (201 in intervention and 198 in control arm). A total of 220 patients (55%) had ID at discharge (i.e., a hepcidin < 41 μg/l). Primary endpoint was not different (medians (IQR) post-ICU LOS 33(13;90) vs. 33(11;90) days for intervention and control, respectively, median difference - 1(- 3;1) days, p = 0.78). D90 mortality was significantly lower in intervention arm (16(8%) vs 33(16.6%) deaths, absolute risk difference - 8.7 (- 15.1 to - 2.3)%, p = 0.008, OR 95% IC, 0.46, 0.22-0.94, p = 0.035), and one-year survival was improved (p = 0.04). CONCLUSION Treatment of ID diagnosed according to hepcidin levels did not reduce the post-ICU LOS, but was associated with a significant reduction in D90 mortality and with improved 1-year survival in critically ill patients about to be discharged after a prolonged stay. TRIAL REGISTRATION www.clinicaltrial.gov NCT02276690 (October 28, 2014; retrospectively registered).
Collapse
Affiliation(s)
- Sigismond Lasocki
- Département Anesthésie Réanimation, CHU Angers, Université D'Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.
| | - Pierre Asfar
- Département Médecine Intensive Réanimation, CHU Angers, Université D'Angers, Angers, France
| | - Samir Jaber
- Département Anesthésie Réanimation, Université de Montpellier, Montpellier, France
| | - Martine Ferrandiere
- Département Anesthésie Réanimation, CHU de Tours, Université de Tours, Tours, France
| | - Thomas Kerforne
- Service D'anesthésie-réanimation, CHU de Poitiers, Université de Poitiers, Poitiers, France
| | - Karim Asehnoune
- Département Anesthésie Réanimation, CHU de Nantes, Université de Nantes, Nantes, France
| | - Philippe Montravers
- Département Anesthésie Réanimation, APHP, HUPNSV, CHU Bichat, Université Paris Diderot Sorbonne, Paris, France
| | - Philippe Seguin
- Département Anesthésie Réanimation, CHU de Rennes, Université de Rennes, Rennes, France
| | - Katell Peoc'h
- INSERM U1149, UFR de Médecine Bichat, Centre de Recherche Sur L'Inflammation, Université de Paris, Paris, France.,APHP Nord Hôpital Universitaire Louis Mourier, Assistance Publique des Hôpitaux de Paris, Colombes, France.,Laboratoire D'Excellence GR-Ex Ou Laboratory of Excellence GR-Ex, Paris, France
| | - Soizic Gergaud
- Département Anesthésie Réanimation, CHU Angers, Université D'Angers, 4 rue Larrey, 49933, Angers Cedex 9, France
| | - Nicolas Nagot
- Département D'information médicale, CHU Montpellier, Université de Montpellier, Montpellier, France
| | - Thibaud Lefebvre
- INSERM U1149, UFR de Médecine Bichat, Centre de Recherche Sur L'Inflammation, Université de Paris, Paris, France
| | - Sylvain Lehmann
- Laboratoire de Biochimie Protéomique Clinique Et IRMB INSERM, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | | |
Collapse
|
3
|
Oczkowski S, Shah A, Aubron C, Wijnberge M, Vlaar APJ. Treating critically ill anemic patients with erythropoietin: less is more. Intensive Care Med 2020; 47:256-257. [PMID: 33034687 DOI: 10.1007/s00134-020-06259-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/19/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Simon Oczkowski
- Department of Medicine, McMaster University, Hamilton, Canada.,Guidelines in Intensive Care, Development and Evaluation (GUIDE) Group, Hamilton, Canada.,Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
| | - Akshay Shah
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK.,Adult Intensive Care Unit, John Radcliffe Hospital, Oxford, UK
| | - Cécile Aubron
- Department of Intensive Care Medicine, Centre Hospitalier Régional Et Universitaire de Brest, site La Cavale Blanche, Université de Bretagne Occidentale, Brest, France
| | - Marije Wijnberge
- Department of Intensive Care Medicine, Amsterdam UMC, Location AMC, Room, C3-430, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.,Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands
| | - Alexander P J Vlaar
- Department of Intensive Care Medicine, Amsterdam UMC, Location AMC, Room, C3-430, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
| | | |
Collapse
|
4
|
Wijnberge M, Rellum SR, Bruin S, Cecconi M, Oczkowski S, Vlaar AP. Erythropoiesis‐stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: A systematic review with meta‐analysis. Transfus Med 2020; 30:433-441. [DOI: 10.1111/tme.12715] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 08/26/2020] [Accepted: 09/03/2020] [Indexed: 12/19/2022]
Affiliation(s)
- Marije Wijnberge
- Department of Anesthesiology Amsterdam UMC, Location AMC Amsterdam The Netherlands
- Department of Intensive Care Amsterdam UMC, Location AMC Amsterdam The Netherlands
| | - Santino R. Rellum
- Department of Anesthesiology Amsterdam UMC, Location AMC Amsterdam The Netherlands
| | - Sanne Bruin
- Department of Intensive Care Amsterdam UMC, Location AMC Amsterdam The Netherlands
| | - Maurizio Cecconi
- Department of Anesthesia and Intensive Care Humanitas Clinical and Research Center‐IRCCS Milan Italy
- Humanitas University Milan Italy
| | - Simon Oczkowski
- Department of Medicine and Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Canada
- Guidelines in Intensive Care, Development and Evaluation (GUIDE) Group Hamilton Canada
| | - Alexander P. Vlaar
- Department of Intensive Care Amsterdam UMC, Location AMC Amsterdam The Netherlands
| |
Collapse
|